Nov 22, 2021
Clinical characterization and treatment outcomes of intracerebral and subarachnoid hemorrhage after vaccination against COVID-19: A systematic review of the literature
- Jin Pyeong Jeon1,
- Chung Liang Chai2,
- Jong Kook Rhim3,
- Jeong Jin Park4,
- Yong Jun Cho1,
- Seung Hun Sheen5
- 1College of Medicine, Hallym University;
- 2Yee Zen General Hospital;
- 3College of Medicine, Jeju National University;
- 4Konkuk University Medical Center;
- 5Bundang CHA Medical Center
- ICH COVID Vaccine
Protocol Citation: Jin Pyeong Jeon, Chung Liang Chai, Jong Kook Rhim, Jeong Jin Park, Yong Jun Cho, Seung Hun Sheen 2021. Clinical characterization and treatment outcomes of intracerebral and subarachnoid hemorrhage after vaccination against COVID-19: A systematic review of the literature. protocols.io https://dx.doi.org/10.17504/protocols.io.bz8vp9w6
License: This is an open access protocol distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Protocol status: In development
We are still developing and optimizing this protocol
Created: November 21, 2021
Last Modified: November 22, 2021
Protocol Integer ID: 55285
Keywords: subarachnoid hemorrhage after vaccination, cerebral hemorrhage, serious adverse reactions after vaccination, coronavirus disease, vaccination increase, vaccination, intracerebral hemorrhage, number of vaccination increase, subarachnoid hemorrhage, infection case, reports of complication, disease, patient prognosis, prognosis
Abstract
As the number of COVID-19 vaccines increases, reports of complications are also increasing. In particular, when cerebral hemorrhage occurs, the prognosis is poor. Here, we aimed to investigating the clinical course of patients who developed intracerebral hemorrhage after COVID-19 vaccination and the patient prognosis through a systematic review.
As coronavirus disease 2019 (COVID-19) hit the world like never before, there were 244,105,621 infection cases and 4,959,347 deaths worldwide as of October 24, 2021. As the number of vaccination increases, reports of death and serious adverse reactions after vaccination are also increasing.
Review title
Clinical characterization and treatment outcomes of intracerebral and subarachnoid hemorrhage after vaccination against COVID-19: A systematic review of the literature
Anticipated or actual start date
20 Novermber 2021
Anticipated completion date
20 February 2022
Stage of review at time of this submission
| Review stage | Started | Completed | |
| Review starge | Yes | No | |
| Piloting of the study selection process | No | No | |
| Formal screening of search results against eligibility criteria | No | No | |
| Data extraction | No | No | |
| Risk of bias (quality) assessment | No | No | |
| Data analysis | No | No |
Funding sources/sponsors
This study received funding from the National Research Foundation of Korea funded by the Ministry of Education
Grant number(s)
2020R1l1A3070726
2021R1A6A3A01087921
Conflict of interest
None
Review question
Participants: Patients of intracerebral and subarachnoid hemorrhage after vaccination against COVID-19
Exposure: Vaccination against COVID-19
Type of vaccination: To compare complications based on various vaccine types
Outcome: Presence of ICH, cerebral venous thrombosis (CVT), thrombosis with thrombocytopenia syndrome (TTS), death
Searches
MEDLINE, EMBASE, and Google Scholar
Condition or domain being studied
As the number of COVID-19 vaccines increases, reports of complications are also increasing. In particular, when cerebral hemorrhage occurs, the prognosis is poor. Here, we aimed to investigating the clinical course of patients who developed intracerebral hemorrhage after COVID-19 vaccination and the patient prognosis through a systematic review.
As coronavirus disease 2019 (COVID-19) hit the world like never before, there were 244,105,621 infection cases and 4, 959,347 deaths worldwide as of October 24, 2021. As the number of vaccination increases, reports of death and serious adverse reactions after vaccination are also increasing.
Participants/population
Specify the participants or populations being studied in the review. The preferred format includes details of both inclusion and exclusion criteria.
Inclusion criteria (Pai 2021):
1. A patient who visited the hospital for ICH after receiving COVID-19 vaccine
2. ICH that occurred within 28 days after vaccination
3. Spontaneous cerebral hemorrhage
Exclusion criteria:
1. ICH after COVID-19 infection
2. Patients with ICH without prior history of COVID-19 vaccination
3. ICH that are caused by after traumatic brain injury
4. ICH that occurred beyond 28 days after vaccination
Definitions:
1. COVID-19 vaccine:
- ChAdOx1 nCoV-20' (AZ),
- mRNA (Pfizer and Moderna),
- Ad26.COV2.S (Johnson & Johnson)
2. Intracerebral hemorrhage (ICH) was defined as hemorrhage in cerebrum as the predominate lesion. Those with concomitant SAH were included in this study. However, pure SAH alone was not included in this study.
3. COVID-19 infection: diagnosed by any means as reported.
References:
Pai M, et al. Vaccine-induced prothrombotic immune thrombocytopenia VIPIT following AstraZeneca COVID-19 vaccination: interim guidance for healthcare professionals in emergency department and inpatient setting. Science Brief of the Ontario COVID-19 Science Advisory Table. 2021;1(21).
Intervention(s), exposure(s)
There is no designated intervention or exposure in this study because the aim of this review is narrative outcome data.
Comparator(s)/control
There is no designated intervention or exposure in this study because the aim of this review is narrative outcome data.
Types of study to be included
Inclusion criteria: all types of article as long as the data is available
1. Randomized studies
2. Non-randomized studies
3. Studies without control: Case series, case reports, brief communication, or other equivalent
Exclusion criteria:
Study not reported in English
Context
Hospital setting
Main outcome(s)
1. Presence of intracerebral hemorrhage (ICH)
2. Presence of cerebral venous thrombosis (CVT)
3. Presence of thrombosis with thrombocytopenia syndrome (TTS)
4. Functional outcome measured by modified Rankin scale at discharge
Measures of effect
Counts of ICH, CVT, TTS
Timing: within 28 days after receiving COVID-19 vaccine
Additional outcome(s)
None
Data extraction (selection and coding)
Dr. Jeon and Dr. Chai work independently on study selection according to the aforementioned inclusion and exclusion criteria. Dr. Jeon and Dr. Chai work independently on extraction of data from included studies using a pre-piloted form.
Risk of bias (quality) assessment
Outcomes listed below is specified to be assessed using GRADE for quality of evidence and presented in the summary of findings (Guyatt, 2011).
All disagreement and accuracy will be resolved by discussion between Jeon and Chai
References:
Gordon H. Guyatt et al. GRADE guidelines: 1. Introduction GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 64 (2011) 383e394 doi: 10.1016/j.jclinepi.2010.04.026
Strategy for data synthesis
Qualitative:
GRADE for the certainty of evidence
Quantitative:
If data is not suitable for pooling, a narrative synthesis will be performed.
Analysis of subgroups or subsets
None
Type and method of review
Epidemiologic, Meta-analysis, Narrative synthesis, COVID-19, Vaccines
Language
English
Other registration details
Will be registered in PROSPERO, with details to be updated when available
Keywords
COVID vaccine, intracerebral hemorrhage, cerebral venous thrombosis, thrombosis with thrombocytopenia syndrome
Current review status
Ongoing